Herbal medicines show potency against Bartonella in test tube
A new study shows that herbal medicines have potent activity in test tubes compared to pharmaceuticals commonly prescribed for the treatment of bartonellosis.
Bartonellosis is a collection of emerging infectious diseases, including cat scratch disease, trench fever, Carrion’s disease, and bacillary angiomatosis. The bacteria can be transmitted via ticks, fleas, lice and sand flies.
This is the first study to find antimicrobial activity of some of these herbal medicines. Published in the journal Infectious Microbes & Diseases, the laboratory study was funded in part by the Bay Area Lyme Foundation.
The study is the first to demonstrate that these three herbal medicines had high activity against stationary phase Bartonella henselae:
- Black walnut (Juglans nigra)
- Cryptolepis (Cryptolepis sanguinolent)
- Japanese knotweed (Polygonum cuspidatum)
The study also confirmed the anti-microbial activity of thee two herbal medicines against the same bacteria:
- Barbat skullcap (Scutellaria barbata)
- Chinese skullcap (Scutellaria baicalensis)
Some also effective against Lyme and Babesia
Three of these – Chinese skullcap, cryptolepis, and Japanese knotweed – have previously been shown, in similar test tube models, to also be effective against both Borrelia burgdorferi, the bacteria that causes Lyme disease, and Babesia duncani, a malaria-like parasite found on the West Coast of the US that causes the disease babesiosis.
These three herbal medicines, as well as black walnut, were shown to be more effective than commonly prescribed antibiotics against Borrelia burgdorferi.
“As many people with Lyme disease are co-infected with other pathogens, these findings, which show that certain herbal medications are effective in the lab against multiple tick-borne infections, are an important advance for the tick-borne disease community,” said co-author Sunjya K. Schweig, MD, Founder and Director, California Center for Functional Medicine and Scientific Advisory Board Member, Bay Area Lyme Foundation.
Collaborating researchers were from Johns Hopkins Bloomberg School of Public Health, California Center for Functional Medicine, FOCUS Health Group, Naturopathic, and Zhejiang University School of Medicine.
“Because so many patients with tick-borne disease do not respond to the standard treatments outlined in medical guidelines, we need research on potential alternatives that can fill this gap and aid in the recovery of patients managing acute and long-term symptoms,” added Dr. Schweig.
Two commonly prescribed antibiotics for tick-borne infections, doxycycline and azithromycin, cleared the persistent form of the bacteria at approximately the same levels as the drug-free control. Comparisons of the pharmaceuticals daptomycin and methylene blue had better activity against stationary phase B. henselae (residual viability of the bacteria reduced to below 40%) than gentamicin, rifampin, and miconazole, which showed relatively better activity (residual viability of the bacteria reduced to below 50%) against stationary phase B. henselae than doxycycline, and azithromycin (residual viability of the bacteria reduced only to 66% and 70% respectively).
These botanical compounds still need to be tested in animals as well as in human clinical trials. While each of these botanical medicines are already in clinical use, it is important for future studies to evaluate them directly in patients using specific clinical treatment regimens, as each have the potential to produce side effects in patients, and should be taken only under the care of a clinician knowledgeable of their capabilities, interactions and toxicities.
Symptoms of Bartonellosis may include fever, lymphadenopathy, malaise, abdominal pain, endocarditis and arthritis. Serious complications can develop in patients for whom the disease progresses, including seizures, cranial nerve palsies, and aseptic meningitis, as well as enlargement of heart, liver and/or spleen, among other symptoms. There is no single treatment effective for Bartonella-associated diseases, and antibiotic recommendations differ depending on specific presentations.
SOURCE OF PRESS RELEASE: Bay Area Lyme Foundation